|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2002-1-11
|
|
pubmed:abstractText |
Temozolomide is a novel oral alkylating agent that is effective against melanoma. Moreover, temozolomide readily crosses the blood-brain barrier and may consequently be effective in patients with brain metastases. This phase II study was performed to assess the efficacy and safety of the combination regimen of temozolomide and docetaxel in patients with advanced metastatic melanoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
420-5
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:11786569-Administration, Oral,
pubmed-meshheading:11786569-Adult,
pubmed-meshheading:11786569-Aged,
pubmed-meshheading:11786569-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11786569-Brain Neoplasms,
pubmed-meshheading:11786569-Dacarbazine,
pubmed-meshheading:11786569-Disease-Free Survival,
pubmed-meshheading:11786569-Female,
pubmed-meshheading:11786569-Humans,
pubmed-meshheading:11786569-Infusions, Intravenous,
pubmed-meshheading:11786569-Male,
pubmed-meshheading:11786569-Melanoma,
pubmed-meshheading:11786569-Middle Aged,
pubmed-meshheading:11786569-Neutropenia,
pubmed-meshheading:11786569-Paclitaxel,
pubmed-meshheading:11786569-Skin Neoplasms,
pubmed-meshheading:11786569-Taxoids,
pubmed-meshheading:11786569-Thrombocytopenia
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
|
|
pubmed:affiliation |
Metaxa's Cancer Hospital, Piraeus, Greece. hesmo@compulink.gr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase II
|
